

## Gouvernement du Québec

An Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32)

**List of Medications****1 January 1997****— Amendment number 2**

**1.** The List of Medications dated 1 January 1997, prepared by the Minister of Health and Social Services pursuant to the Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32), published in Part 2 of the *Gazette officielle du Québec* of 24 December 1996 and amended by Amendment Number 1, published in Part 2 of the *Gazette officielle du Québec* of 5 February 1997, is further amended, in Appendix III, by inserting the following after the brand name PROGRAF Caps. 5 mg:

|       |                        |         |
|-------|------------------------|---------|
| Roche | PROTOPIN Inj. Pd. 5 mg | 2 vials |
| Roche | PROTOPIN Inj. Pd. 5 mg | 2 vials |

**2.** Appendix IV of the List is amended

(1) by striking out paragraph 6;

(2) by inserting the following after paragraph 13:

(13.1) CARVEDILOL tab., Coreg: for the treatment of stable symptomatic congestive heart failure in patients receiving a diuretic and an angiotensin converting enzyme inhibitor;

(3) by inserting the following after paragraph 20:

(20.1) DIHYDROERGOTAMINE (mesylate) nasal spray, Migranal: for the treatment of nonprophylactic episodes of migraines in patients for whom treatment with analgesics or with other drug therapies is ineffective;

(4) by replacing paragraph 29 by the following:

(29) FAMCICLOVIR tab., Famvir:

(a) for the early treatment of zona, that is, within 48 to 72 after the appearance of lesions;

(b) for the curative treatment of severe infectious episodes of recurring genital herpes;

(5) by replacing, in paragraph 47 of the English version, the words “although with assistance” with the words “even if they require assistance”;

(6) by inserting the following after paragraph 72:

(72.1) SOMATREM inj. pd., Protropin:

(a) for the treatment of children suffering from delayed growth caused by insufficient secretion of the endogenous growth hormone, except children who are carriers of a Turner’s syndrome or are suffering from achondroplasia or from delayed growth of a genetic or familial type, children whose bone age has reached 15 years for girls and 16 years for boys, and children whose growth rate falls below 4 cm per year, evaluated on two consecutive visits at a 3-month interval, where they meet the following criteria:

i. untermiated growth and growth rate for their bone age less than the 25th percentile, calculated over at least a one-year period; the one-year observation period does not apply to young children suffering from hypoglycemia secondary to a growth hormone deficiency;

ii. serum concentration of somatotrophin less than 8 ng/mL measured by two pharmacological tests, or serum concentration between 8 and 10 ng/mL if the tests are repeated twice at a 6-month interval;

(b) for the treatment of children suffering from delayed growth related to chronic renal failure until renal transplant;

(7) by replacing paragraph 77 by the following:

(77) VALACYCLOVIR (hydrochloride) tab., Valtrex:

(a) for the early treatment of zona, that is, within 48 to 72 hours after the appearance of lesions;

(b) for the curative treatment of severe infectious episodes of recurring genital herpes.

**3.** The List is amended

(1) in sub-subdivision 8:12.28, OTHER ANTIBIOTICS, by striking out, under the generic name CLINDAMYCIN PHOSPHATE, 150 mg/mL injectable solution, the brand name CLINDAMYCINE and the accompanying information;

(2) in subdivision 8:36, URINARY ANTI-INFECTIVES, by replacing the amount 67.50 by 61.75 with respect to MACROBID, 100 mg capsule;

(3) in division 10:00, ANTINEOPLASTIC DRUGS, by inserting the following after the information concerning SODIUM AMENTHOPTERIN (SODIUM):

**ANASTROZOLE**

Tab. 1 mg

+ | 02224135 | Arimidex | Zeneca | 30 | 148.50 | 4.9500 |

(4) in subdivision 24:04, CARDIAC DRUGS:

i. by replacing the amount 188.30 by 188.15 and the amount 0.3766 by 0.3763 with respect to APO-ATENOL, GEN-ATENOLOL, NOVO-ATENOL and TENOLIN, 50 mg tablet;

ii. by replacing the amount 112.98 by 112.89 and the amount 0.3766 by 0.3763 with respect to ATENOLOL-50, 50 mg tablet;

iii. by replacing the amount 207.50 by 181.75 and the amount 0.4150 by 0.3635 with respect to APO-DILTIAZ SR, 60 mg long-acting capsule and by replacing the amount 311.25 by 272.75 and the amount 0.6225 by 0.5455 with respect to APO-DILTIAZ SR, 90 mg long-acting capsule;

(5) in sub-subdivision 28:08.04, NONSTEROID ANTI-INFLAMMATORIES:

i. by replacing the amount 23.75 by 22.27 and the amount 0.7917 by 0.7423 with respect to NOVO-DIFENAC, 50 mg suppository and by replacing the amount 31.90 by 29.99 and the amount 1.0633 by 0.9997 with respect to NOVO-DIFENAC, 100 mg suppository;

ii. by replacing the amount 21.33 by 21.15 and the amount 0.7110 by 0.7050 with respect to NOVO-METHACIN and INDOTEC, 50 mg suppository and by replacing the amount 7.11 by 7.05 and the amount 0.7110 by 0.7050 with respect to RHODACINE, 50 mg suppository;

iii. by replacing the amount 33.11 by 29.80 and the amount 1.1037 by 0.9933 with respect to NOVO-KETO, PMS-KETOPROFEN, RHODIS 100 and ORAFEN, 100 mg suppository;

(6) in sub-subdivision 28:08.08, OPIATE AGONISTS, under the generic name MORPHINE SULFATE:

i. by inserting the following after the information concerning the brand name M-ESLON, 15 mg long-acting capsule:

|              |        |       |     |       |        |
|--------------|--------|-------|-----|-------|--------|
| L.A. Caps.   | 20 mg  |       |     |       |        |
| +   02184435 | Kadian | Knoll | 100 | 68.00 | 0.6800 |

ii. by replacing the amount 35.50 by 34.28 and the amount 0.7100 by 0.6856 with respect to M-ESLON, 30mg long-acting capsule;

iii. by inserting the following after the information concerning the brand name M-ESLON, 30 mg long-acting capsule:

|              |        |       |     |        |        |
|--------------|--------|-------|-----|--------|--------|
| L.A. Caps.   | 50 mg  |       |     |        |        |
| +   02184443 | Kadian | Knoll | 100 | 125.00 | 1.2500 |

iv. by replacing the amount 62.50 by 60.17 and the amount 1.2500 by 1.2034 with respect to M-ESLON, 60 mg long-acting capsule;

v. by inserting the following after the information concerning the brand name M-ESLON, 60 mg long-acting capsule:

|              |        |       |    |        |        |
|--------------|--------|-------|----|--------|--------|
| L.A. Caps.   | 100 mg |       |    |        |        |
| +   02184451 | Kadian | Knoll | 50 | 109.00 | 2.1800 |

(7) in sub-subdivision 28:16.04, ANTIDEPRESSANTS:

i. by replacing the amount 129.50 by 127.20 and the amount 0.2590 by 0.2544 with respect to DESIPRAMINE, APO-DESIPRAMINE, PMS-DESIPRAMINE and DESIPRAMINE-25, 25 mg tablet and by replacing the amount 25.90 by 25.44 and the amount 0.2590 by 0.2544 with respect to NOVO-DESIPRAMINE, 25 mg tablet;

ii. by replacing the amount 316.90 by 316.70 and the amount 0.6338 by 0.6334 with respect to PMS-DESIPRAMINE, 75 mg tablet;

iii. by replacing the amount 30.32 by 30.30 and the amount 0.3032 by 0.3030 with respect to PMS-NORTRIPTYLINE, 25 mg tablet;

(8) in sub-subdivision 28:16.08, TRANQUILIZERS, by replacing the amount 39.70 by 31.76 with respect to MODECATE CONCENTRE, 100 mg/mL intramuscular injectable solution;

(9) in sub-subdivision 28:24.08, BENZODIAZEPINES :

i. by replacing the amount 7.70 by 6.93 and the amount 0.0770 by 0.0693 with respect to SYN-BROMAZEPAM, APO-BROMAZEPAM, GEN-BROMAZEPAM and BROMAZEPAM-1.5, 1.5 mg tablet;

ii. by replacing the amount 52.50 by 47.25 and the amount 0.1050 by 0.0945 with respect to SYN-BROMAZEPAM, APO-BROMAZEPAM, GEN-BROMAZEPAM and BROMAZEPAM-3, 3 mg tablet;

iii. by replacing the amount 76.65 by 69.00 and the amount 0.1533 by 0.1380 with respect to SYN-BROMAZEPAM, APO-BROMAZEPAM, GEN-BROMAZEPAM and BROMAZEPAM-6, 6 mg tablet;

(10) in sub-subdivision 28:24.92, MISCELLANEOUS:

i. by replacing the amount 197.00 by 178.14 and the amount 0.7880 by 0.7126 with respect to TRYPTAN, 500 mg capsule or tablet;

ii. by replacing the amount 75.40 by 56.55 and the amount 0.1508 by 0.1131 with respect to NOVOMEPRAZINE and NOZINAN, 25 mg tablet;

iii. by replacing the amount 114.20 by 85.65 and the amount 0.2284 by 0.1713 with respect to NOVOMEPRAZINE and NOZINAN, 50 mg tablet;

(11) in subdivision 40:28, DIURETICS, by replacing the amount 35.45 by 31.90 and the amount 0.3545 by 0.3190 with respect to APO-INDAPAMIDE and GEN-INDAPAMIDE, 2.5 mg tablet;

(12) in sub-subdivision 52:04.04, ANTIBIOTICS, by replacing the amount 2.49 by 2.39 with respect to ALCOMICIN, GENTACIDIN, OPHTAGRAM, DIOGRAM, OCUGRAM, GENTAMICIN, PMS-GENTAMICINE, R.O. GENTYCIN, SCHEINPHARM GENTAMICIN and GARATEC, 0.3 % ophthalmic solution;

(13) in subdivision 52:08, ANTI-INFLAMMATORIES, by replacing the amount 13.64 by 12.27 with respect to GEN-BECLO AQ, 0.05 mg/dose nasal spray or mist and by replacing the amount 13.64 by 12.28 with respect to DIPROPIONATE DE BECLOMETHASONE AQ, 0.05 mg/dose nasal spray or mist;

(14) in subdivision 84:06, ANTI-INFLAMMATORIES:

i. by replacing the amount 20.40 by 20.34 and the amount 0.4080 by 0.4068 with respect to PROPIONATE DE CLOBETASOL, GEN-CLOBETASOL and NOVOCLOBETASOL, 0.05 % topical cream;

ii. by replacing the amount 20.40 by 20.34 and the amount 0.4080 by 0.4068 with respect to PROPIONATE DE CLOBETASOL, GEN-CLOBETASOL and NOVOCLOBETASOL, 0.05 % topical ointment;

(15) in division 92:00, OTHER DRUGS:

i. by replacing the amount 28.15 by 25.30 and the amount 0.2815 by 0.2530 with respect to ENDOLEVODOPA/CARBIDOPA, APO-LEVOCARB and PRO-LECARB-100/10, 100 mg-10 mg tablet;

ii. by replacing the amount 210.00 by 189.25 and the amount 0.4200 by 0.3785 with respect to ENDOLEVODOPA/CARBIDOPA, APO-LEVOCARB and PRO-LECARB-100/25, 100 mg-25 mg tablet;

(16) in the division entitled EXCEPTIONAL MEDICATIONS:

i. by replacing the amount 480.70 by 439.13 and the amount 0.9614 by 0.8783 with respect to AVIRAX, 200mg tablet;

ii. by replacing the amount 184.40 by 172.88 and the amount 1.8440 by 1.7288 with respect to AVIRAX, 400 mg tablet;

iii. by replacing the amount 943.50 by 849.90 and the amount 3.7740 by 3.3996 with respect to AVIRAX, 800 mg tablet;

(17) in the division entitled EXCEPTIONAL MEDICATIONS, by striking out the generic name ANASTROZOLE and the accompanying information;

(18) in the division entitled EXCEPTIONAL MEDICATIONS, by inserting the following after the generic name CAPSAICIN and the accompanying information:

#### CARVEDILOL

|  |          |  |  |  |  |
|--|----------|--|--|--|--|
| Tab.   | 3.125 mg |  |  |  |  |
| +   02229650   Coreg   SBP   100   127.00   1.2700 |          |  |  |  |  |

|  |         |  |  |  |  |
|--|---------|--|--|--|--|
| Tab.   | 6.25 mg |  |  |  |  |
| +   02229651   Coreg   SBP   100   127.00   1.2700 |         |  |  |  |  |

|  |         |  |  |  |  |
|--|---------|--|--|--|--|
| Tab.   | 12.5 mg |  |  |  |  |
| +   02229652   Coreg   SBP   100   127.00   1.2700 |         |  |  |  |  |

|  |       |  |  |  |  |
|--|-------|--|--|--|--|
| Tab.   | 25 mg |  |  |  |  |
| +   02229653   Coreg   SBP   100   127.00   1.2700 |       |  |  |  |  |

(19) in the division entitled EXCEPTIONAL MEDICATIONS, by inserting the following after the generic name DICLOFENAC SODIUM and the accompanying information:

**DIHYDROERGOTAMINE MESYLATE**

|   |         |  |  |  |  |
|---|---------|--|--|--|--|
| Vap. nasal  | 4 mg/mL |  |  |  |  |
| +   02228947   MIGRANAL   Sandoz   3   27.15   9.0500 |         |  |  |  |  |

(20) in the division entitled EXCEPTIONAL MEDICATIONS, by inserting the following under the generic name FAMCICLOVIR and before FAMVIR, 500 mg tablet:

|   |        |  |  |  |  |
|---|--------|--|--|--|--|
| Tab.  | 125 mg |  |  |  |  |
| +   02229110   Famvir   SBP   10   25.30   2.5300 |        |  |  |  |  |

|  |        |  |  |  |  |
|--|--------|--|--|--|--|
| Tab.   | 250 mg |  |  |  |  |
| +   02229129   Famvir   SBP   30   102.00   3.4000 |        |  |  |  |  |

(21) in the division entitled EXCEPTIONAL MEDICATIONS, by replacing the amount 1.93 by 1.54 with respect to ENSURE HYPER-PROTEINE, 235 mL liquid;

(22) in the division entitled EXCEPTIONAL MEDICATIONS, by replacing the amount 4.50 by 4.16 and the amount 0.3000 by 0.2773 with respect to ISOPTO TEARS and EYELUBE, 0.5 % ophthalmic solution and by replacing the amount 5.59 by 4.70 and the amount 0.3727 by 0.3133 with respect to EYELUBE, 1 % ophthalmic solution;

(23) in the division entitled EXCEPTIONAL MEDICATIONS, by replacing the amount 14.70 by 14.50 and the amount 0.0147 by 0.0145 with respect to LACTULAX and COMALOSE-R, 666.7 mg/mL syrup;

(24) in the division entitled EXCEPTIONAL MEDICATIONS:

i. by replacing the amount 35.40 by 23.84 and the amount 3.5400 by 2.3840 with respect to ALLEVYN ADHESIF, 7.5 cm X 7.5 cm dressing;

ii. by replacing the amount 86.20 by 57.91 and the amount 8.6200 by 5.7910 with respect to ALLEVYN ADHESIF, 12.5 cm X 12.5 cm dressing;

iii. by replacing the amount 24.39 by 11.57 with respect to ALLEVYN ADHESIF, 17.5 cm X 17.5cm dressing;

iv. by replacing the amount 32.84 by 22.89 with respect to ALLEVYN ADHESIF, 22.5cmX 22.5 cm dressing;

(25) in the division entitled EXCEPTIONAL MEDICATIONS:

i. by replacing the amount 48.50 by 46.40 and the amount 0.0485 by 0.0464 with respect to PMS-SENNOSIDES and SENNATABS, 8.6 mg tablet and by replacing the amount 24.25 by 23.20 and the amount 0.0485 by 0.0464 with respect to SENNOSIDES, 8.6 mg tablet;

ii. by replacing the amount 58.20 by 55.50 and the amount 0.0582 by 0.0555 with respect to PMS-SENNOSIDES, 12 mg tablet and by replacing the amount 29.10 by 27.75 and the amount 0.0582 by 0.0555 with respect to SENNOSIDES, 12 mg tablet;

(26) in the division entitled EXCEPTIONAL MEDICATIONS, by inserting the following after the generic name SOMATOTROPHINE and the accompanying information:

**SOMATREM**

|  |      |  |  |  |  |
|--|------|--|--|--|--|
| Inj. Pd.   | 5 mg |  |  |  |  |
| +   02204584   PROTROPIN   Roche   2   490.00   245.0000 |      |  |  |  |  |

|  |       |  |  |  |  |
|--|-------|--|--|--|--|
| Inj. Pd.   | 10 mg |  |  |  |  |
| +   02204576   PROTROPIN   Roche   2   960.00   480.0000 |       |  |  |  |  |

4. This Amendment comes into force on 7 April 1997.

1353